The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

The occurrence of neuroleptic malignant syndrome in patients on antipsychotic therapy and factors influencing its development ...

Data from the federal government shows that Mississippi consistently ranks in the top five in the nation for its rates of ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

The use of antipsychotics for schizophrenia was associated with higher risk for severe cases of COVID-19 and non–COVID-19 respiratory infections but not mild infection.

Explore hyposexuality in bipolar disorder, including symptoms like low libido, reduced sexual desire, and difficulty ...

A new study in the Journal of Child and Adolescent Psychopharmacology estimates the incidence of neuroleptic malignant ...

Vortioxetine, identified using a novel screening method, may enhance glioblastoma treatment alongside standard therapies, ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

There is no correlation between high-density lipoprotein cholesterol (HDL-C) levels and a patient's risk for developing ...